FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662

February 12, 2018

To,

BSE Ltd., Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai - 400 001

Ref.: BSE Scrip Code - 539730

Subject: Outcome of Board Meeting

Dear Sir / Madam,

In compliance to Regulation 33 of SEBI Listing Regulations, 2015; we wish to inform you that the Board of Directors of the Company, at its Meeting held on Monday, February 12, 2018, have considered and approved the Unaudited Financial Results of the Company for Quarter & Nine months ended December 31, 2017; along with the Limited Review Report issued by M/s. Savla & Associates, Statutory Auditors of the Company; the copies of which are attached hereunder.

The Meeting of the Board Commenced at 2:00 P.M. and concluded at 5:00 P.M.

Kindly take the same on your Records.

Thanking you,

For Freezen Pharmaceuticals Limited DIRECTOR Encl. - A/a



FREDUN PHARMACEUTICALS LIMITED


Compassionate Healthcare



CIN No: L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2017

		_		Rs, 1n	Lacs		
		(Juarter Ended		Nine Months Ended		Year Ended
	Ī	Unaudited			Unau	dited	Audited
	PARTICULARS	31.12.2017	30.09.2017	31.12.2 0 16	31.12.2017	31.12.2016	31.03.2017
1	Income from Operations						
	Net Sales /IncomeFrom Operation (Net of Excise Duty)	1367.08	1504.12	1250.40	3786.14	3933.97	5669.62
2	Other Operating Income	21.33	45.57	138.67	82.23	159.98	191.38
3	Total income from operatoins (net)	1388.41	1549.69	1389,07	3868.37	4093.95	5861.00
4	Expenses						
	a) Cost of Material Consumed	1161.41	1091.83	958.10	2957.68	2527.55	3395.85
	b) Purchases of stock -in-trade	0.00	0.00	0.00	0.00	0.00	23.68
	c) Changes in inventories of finished goods, work-in-	(205.15)	(14.73)	(92.22)	(339.12)	123.00	298.35
	d) Finance Costs	52.85	74.04	35.63	163.00	126.61	187.48
	e) Employess benefits expenses	76.46	159.52	136.63	332.24	339.51	491.82
	f) Depreciation and amortisation expenses	28.39	34.40	22.64	85.18	65.39	113.58
	g) Other Expenses	253.80	153.99	314.24	553.07	788.12	1125.26
	Total expenses	1367.76	1499.05	1375.02	3752.05	3970.18	5636.02
5	Profit/(Loss) from ordinary activities before exceptional	20.65	50.64	1373.02	116.32	123.77	224.98
	Exceptional items / Prior Period Item	(0.21)	(0,07)	0.00			
6	Profit/(Loss) from ordinary activities before tax (5-6)	· · ·	· · ·		(0.28)	(1.21)	(2.39) 222.59
/		20.44 0.00	50,57	14.05	116.04	122.56	
8	Tax Expenses		7.00	0.00	15.00	15.00	79.85
9	Profit/(Loss) from continuing operations	20.44	43.57	14.05	101.04	107.56	142.74
	Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
E	Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/ (Loss) for the period	0.00	0.00	0.00	0.00	0.00	0.00
14	Other comprehensive Income						
	A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be re-	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be re-classified to	0.00	0.00	0.00	0.00	0.00	0.00
	Paid up Equity Share Capital (Face Value of Rs-10/- each)	294.72	294.72	237.45	294.72	235.24	237.45
	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	238.55
17	Earning per Share (EPS) (before & after extra ordinary						
	- Basic/ Diluted Earning Per Share (Rs.)	0.69	1.48	0.59	3,43	4.57	6.01
A	1) Public Shareholding						
	Number of shares	1174025	1174025	601290	1174025	601290	601290
	Percentage of shareholding	40.14	40.14	25.56	40.14	25.56	25.50
	Promoters and promotor group shareholding						
	a) Pledged/Encumbured						
1	- Number of shares	-	-	-	-	-	·
	- Percentage of shares (as a % of total shareholding of						
	Promoters and Prompter Group)	-	-	-	-	-	-
	- Percentage of shares (as a % of total share capital of the						
	Company) b) Non-encumbered	-	-	-	-	-	-
	- Number of shares	1751110	1751110	1751110	1751110	1751110	1751110
	- Number of shares - Percentage of shares (as a % of total shareholding of	1/51110	1/51110	1/51110	1/31110	1/51110	1/51110
	Promoters and Prompter Group)	100%	100%	100%	100%	100%	6 100%
	Company)	59.86					
<u> </u>	(. 57.00	. 57.00	1 1-1-1	, 57.00		



FREDUN PHARMACEUTICALS LIMITED Compassionate Healthcare

CIN No: L24239MH1987PLC043662

NOTES:-

1) The above results were taken on record by the Board Of Directors at the meeting held on 12.02.2018

2) Previous year's figures have been regrouped/rearranged wherever necessary.

3) During the quarter ended 31st Dec 2017 there are no investor's complaints pending & no investor's complaints were received by the company during this period.

4) Provision for deferred tax as applicable will be made at the end of the year

5) Dividend on Preference shares will be considered at the year end.

6) The above result have already been approve by the Audit Comittee of the board

7) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April, 2016.

8) Employee Benefit Expense

Particular	Q	Quarter Ended			Nine Months Ended	
· · · · · · · · · · · · · · · · · · ·	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
Break – up of Employee Benefit						
Salary & Wages	7584735.00	12442475.00	10248676.00	25645435.00	26885489.00	39156162.00
Director Remuneration	1230000.00	1230000.00	1230000.00	3690000.00	3690000.00	4920000.00
Contributionn to Provident and Other Funds	588203.00	605376.00	576895.00	1594744.00	1406194.00	2632033.00
Share Base Payment to employees	0.00	0.00	0.00	0.00	0.00	0.00
Staff Welfare Expenses	633711.00	1358654.00	539846.00	2267328.17	1214447.00	1752172.34

9) Gain/ Loss on account of Foreign Exchange Fluctuation (Included in other Income)

Particular		Quarter Ended			Nine Months Ended	
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
Gain / Loss on Account of Foreign Exchange	198699.79	0.00	163766.25	0.00	0.00	673040.12
Fluctuation (Add in Other Income)						
Loss on Account of Foreign Exchange	0.00	-740372.00	0.00	-541672.21	-72390.78	0.00
(Record In Indirect Expenses)						

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031, (INDIA) Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404. Phone: 91-22-4031 8111 Fax: 91-22-4031 8133 E-mail: business@fredungroup.com Web: www.fredungroup.com FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662

10) Reconciliation of Net Profit between Previous GAAP and IND AS

Rs. in Lacs

			AND IN DICO
	Quarter ended	31.12.2017	
	I- GAAP	Effect of	IND -AS
Income from Operations			
Net Sales /IncomeFrom Operation (Net of Excise Duty)	1367.08	-	1367.08
Other Operating Income	21.33	-	21.33
Total income from operatoins (net)	1388.41	-	1388.41
Expenses			
a) Cost of Material Consumed	1161.41	-	1161.41
b) Purchases of stock -in-trade	0.00	-	0.00
c) Changes in inventories of finished goods, work-in-	(205.15)	-	(205.15)
d)Finance Costs	52.85	-	52.85
e) Employess benefits expenses	76.46	-	76.46
f) Depreciation and amortisation expenses	28.39	-	28.39
g) Other Expenses	253.80	-	253.80
Total Expenditure	1367.76	-	1367.76
Profit/(Loss) from ordinary activities before exceptional	20.65	-	20.65
Exceptional items / Prior Period Item	0.00	-	0.00
Profit/(Loss) from ordinary activities before tax (5-6)	20.65	-	20.65
Tax Expenses	0.00		0.00
Profit/(Loss) from continuing operations	20.65	-	20.65
Profit/(Loss) from discontinued operations	0.00	-	0.00
Tax Expense of discontinued operations	0.00	-	0.00
Profit/(Loss) from discontinued operations after tax	0.00	-	0.00
Profit/ (Loss) for the period	20.65	-	20.65
Other comprehensive Income	0.00		0.00
Total Comprehensive Income for the period	20.65		20.65

PLACE: MUMBAI

DATE: 12.02.2018

FOR FREDUN PHARMACEUPICALS LIMITED MANAGING DIRECTOR

Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W), MUMBAI - 400 031.

PHONE : 24102526, 24112526

FAX: 24132121

LIMITED REVIEW REPORT

TO THE BOARD OF DIRECTORS OF FREDUN PHARMACEUTICALS LTD 26,Manoj Industries Premises, G.P.Ambekar marg, Wadala, Mumbai – 400 031.

- 1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended December 31, 2017 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other recognized accounting policies to the extent applicable, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEB1 (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MUMBAI, February 12, 2018

FOR SAVLA & ASSOCIATES Chartered Accountants (Firm Registration No. 109361W) DEEPAK G. SAVLA

(Partner) Membership No. : 043901